U.S. Pharma Packaging Films Market Size, Share & Forecast 2026–2032

ID: MR-11902 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Pharma Packaging Films
  • ✓Market Size 2024: USD 1.42 billion
  • ✓Market Size 2032: USD 2.28 billion
  • ✓CAGR: 6.1%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Serialization Favors Scaled Converters: Amcor and Constantia Flexibles can absorb DSCSA serialization retooling, while smaller converters lacking in-line print verification are losing generic-drug tenders. Buyers should treat serialization-ready printing as a mandatory qualification gate, not a premium feature.
FINDING 02
Recycling Mandates Favor Mono-Materials: The consensus holds that state extended producer responsibility laws will shrink pharmaceutical film demand. California SB 54 and Maine's LD 1044 instead shift volume toward mono-material polyethylene structures, favoring Berry Global and Winpak over multilayer PET-laminate incumbents.
ANALYST RECOMMENDATION

Analyst Recommendation — Qualify Dual Serialized Suppliers: Procurement directors at U.S. generic and biologics manufacturers should qualify two serialization-capable lidding film suppliers before 27 November 2026, when small-dispenser DSCSA obligations take effect. Dual sourcing removes single-converter risk while Medicare negotiated prices begin pressuring unit packaging budgets.

Pharma packaging films in the U.S.: Market Overview

The U.S. pharma packaging films market was valued at USD 1.42 billion in 2024 and is forecast to reach USD 2.28 billion by 2032, growing at 6.1% annually. Films are used in blister lidding, sachets, stick packs, and pouch structures, with PVC, PET, aluminum foil, and polyolefin laminates dominating. Demand concentrates among generic oral solid producers and contract packagers clustered in New Jersey, Pennsylvania, Indiana, and North Carolina, close to wholesaler distribution hubs.

Market structure reflects regulation more than pure commercial dynamics. FDA current good manufacturing practice rules under 21 CFR 211.94 and 211.122 require validated container-closure systems, so film qualification cycles run 12 to 18 months. This favors incumbents such as Amcor and Constantia Flexibles. Private converters have led material innovation, while federal and state government has been the dominant force in setting the specifications that shape product design.

Policy-Driven Growth in U.S. Pharma Packaging Films

The Drug Supply Chain Security Act, enacted under Title II of the Drug Quality and Security Act of 2013, requires unit-level product tracing and serialized labeling across the distribution chain. Printed serial numbers, lot data, and expiry codes must remain legible on lidding films. Each serialized package needs a print-receptive film, so compliance volume translates directly into film substitution rather than discretionary upgrades for generic manufacturers.

Federal pricing policy and state packaging law add two further demand channels. Under the Inflation Reduction Act of 2022, Medicare negotiated prices for the first ten selected drugs take effect 1 January 2026, pressuring generic and biosimilar makers to optimize unit packaging costs. California SB 54 requires 65% of plastic packaging to be recycled by 2032, steering buyers toward recyclable mono-material films rather than multilayer structures.

Regulatory Barriers and Compliance Costs

Container-closure validation is the principal barrier. FDA requires packaging components to be covered by Type III Drug Master Files under 21 CFR 314.420, and USP General Chapters <1663> and <1664> set the extractables and leachables expectations that reviewers apply. Typical qualification adds 9 to 14 months and USD 250,000 to 600,000 per film structure, overseen by the Office of Pharmaceutical Quality within the Center for Drug Evaluation and Research.

Environmental and trade rules add further cost. Maine's Packaging Stewardship and Extended Producer Responsibility law (LD 1044, 2021) and Oregon's SB 582 (2021) impose producer fees administered by Maine DEP and Oregon DEQ, while Colorado's SB 21-260 is administered by CDPHE. Section 301 List 3 tariffs apply at 25% to many Chapter 39 plastic film imports from China, and reciprocal tariffs introduced in April 2025 under IEEPA raised landed costs by an estimated 8% to 12%.

Policy-Created Opportunities in the U.S.

Strategic stockpiling creates procurement openings. The executive order "Filling the Strategic Active Pharmaceutical Ingredients Reserve," signed on 13 August 2025, directs federal stockpiling of critical active ingredients, and reserve stock requires domestically qualified primary and secondary packaging. Converters with U.S.-based film extrusion and validated DMF filings can secure these contracts ahead of import-dependent competitors.

Recyclable mono-material films represent a second opportunity. Demand for polyethylene-based blister and pouch films that satisfy California SB 54 and Maine LD 1044 recyclability criteria is rising among generic manufacturers. Serialization-ready print capability on these same structures allows suppliers to address both recycling and DSCSA requirements through one qualified product.

Market at a Glance

MetricValue
Market Size 2024USD 1.42 billion
Market Size 2032USD 2.28 billion
Growth Rate (CAGR)6.1%
Most Critical Decision FactorValidated serialization and extractables compliance
Largest RegionNortheast and Midwest U.S.
Competitive StructureConsolidated; top five suppliers hold majority share

Leading Market Participants

  • Amcor plc
  • Constantia Flexibles
  • Berry Global
  • Sealed Air
  • Huhtamaki
  • Klöckner Pentaplast
  • ProAmpac
  • Mondi
  • Winpak
  • Glenroy

Regulatory and Policy Environment

The primary legislation is the Drug Supply Chain Security Act under Title II of Public Law 113-54, administered by the FDA's Center for Drug Evaluation and Research. Trading partners must exchange transaction information, transaction history, and transaction statements, and must verify product identifiers at the dispensing level. Packaging components remain subject to cGMP requirements under 21 CFR Part 211 and Type III Drug Master File filings. Small-dispenser DSCSA obligations take effect 27 November 2026, forcing repackagers and small pharmacies to adopt serialization-compliant packaging.

Compared with regional peers, the U.S. framework is more fragmented but less prescriptive on pharmaceutical packaging specifically. The EU Packaging and Packaging Waste Regulation, (EU) 2025/40, applies from 12 August 2026 and sets harmonized recyclability and recycled-content targets across member states. Canada's Federal Plastics Registry, operating under the Canadian Environmental Protection Act, imposes national reporting obligations. U.S. producers instead face a patchwork of state extended producer responsibility laws, with compliance varying by jurisdiction.

Long-Term Policy Outlook for U.S. Pharma Packaging Films

Several policy milestones will shape the market through 2032. Small-dispenser DSCSA compliance concludes in November 2026, California SB 54 requires a 65% plastic packaging recycling rate by 2032, and Medicare negotiation expands to 20 drugs per year from 2028 under the Inflation Reduction Act. Additional states are expected to adopt extended producer responsibility frameworks modeled on Maine and Oregon.

These changes will reshape supplier economics. Mono-material polyethylene and serialization-ready structures will displace multilayer PET-laminate incumbents, while reserve stockpiling and tariff exposure will favor U.S.-based extrusion capacity. Consolidation among top-tier converters will accelerate as smaller firms struggle to fund validation, serialization retooling, and extended producer responsibility compliance simultaneously.

Frequently Asked Questions

The Drug Supply Chain Security Act, enacted under Title II of the Drug Quality and Security Act of 2013, sets the serialization and tracing requirements. FDA's Center for Drug Evaluation and Research enforces it.
Packaging films must be covered by a Type III Drug Master File under 21 CFR 314.420 and support the container-closure validation required by 21 CFR Part 211. Extractables and leachables data should follow USP General Chapters <1663> and <1664>.
Maine's LD 1044, Oregon's SB 582, and Colorado's SB 21-260 apply producer fees to packaging generally, including films used in pharmaceutical products. California SB 54 imposes recyclability and recycling-rate targets that cover these films.
Section 301 List 3 tariffs apply at 25% to many Chapter 39 plastic film imports from China. Reciprocal tariffs introduced in April 2025 under IEEPA have added further duty on Asian film and resin supply.
Small-dispenser DSCSA obligations take effect 27 November 2026, and the EU Packaging and Packaging Waste Regulation applies from 12 August 2026 for exporters. California SB 54 targets apply from 2032.

Market Segmentation

By Material Type
  • PET-based laminates
  • Aluminum foil laminates
  • PVC and PVDC films
  • Polyolefin mono-material films
  • Oriented polyamide laminates
By Packaging Format
  • Blister lidding films
  • Sachets and stick packs
  • Pouches
  • Strip packaging films
By End User
  • Generic oral solid manufacturers
  • Biologics and injectables producers
  • Contract packagers
  • Consumer health manufacturers

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Pharma Packaging Films - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Material Type Insights
4.1 PET-based laminates
4.2 Aluminum foil laminates
4.3 PVC and PVDC films
4.4 Polyolefin mono-material films
4.5 Others
Chapter 05 Packaging Format Insights
5.1 Blister lidding films
5.2 Sachets and stick packs
5.3 Pouches
5.4 Strip packaging films
5.5 Others
Chapter 06 End User Insights
6.1 Generic oral solid manufacturers
6.2 Biologics and injectables producers
6.3 Contract packagers
6.4 Consumer health manufacturers
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Amcor plc
7.2.2 Constantia Flexibles
7.2.3 Berry Global
7.2.4 Sealed Air
7.2.5 Huhtamaki
7.2.6 Klöckner Pentaplast
7.2.7 ProAmpac
7.2.8 Mondi
7.2.9 Winpak
7.2.10 Glenroy
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.